-0.010 (-0.65%)
Range 1.500 - 1.598   (6.53%)
Open 1.530
Previous Close 1.540
Buy Price 1.520
Buy Volume 12
Sell Price 1.540
Sell Volume 8
Volume 277,241
Value -
Measurement Type Value
EPS (USD) -0.359
Trailing EPS (USD) -0.316
NAV (USD) 0.239
Cash In Hand (USD) 0.113
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 6.452
Price / Cash In Hand 13.677
Issued & Paid-up Shares 11,846,800
Treasury Shares -
Market Cap (M) 18.244
Par Value (USD) n.a.
Beta - 75 Days 1.344
R-Squared - 75 Days(%) 0.27
Beta - 500 Days 0.412
R-Squared - 500 Days(%) 0.5
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 14 Aug 2020 04:00.
Data powered by
View All Events


MYOS Corporation is engaged in the discovery, development and commercialization of therapeutic products, nutritional supplements and other technologies to improving the health and performance of muscle tissue. The Company earns revenues through the sale and distribution of MYO-T12. The Company is continuing to develop additional channels for distributing its products in other markets. As of December 31, 2013, the Company earns revenues from the distribution of MYO-T12, its platform dietary supplement product. As of December 31, 2013, the Company markets two Bionutritional products to the general public. The Company is selling its platform ingredient MYO-T12, branded as MYO-X, through national specialty retailers and e-tailers such as GNC, Vitamin Shoppe, bodybuilding.com and Amazon.com. The Company�s product pipeline seeks to develop formulations of its myostatin-inhibiting products to target specific mechanisms involved in maintaining lean muscle mass and function.

Loading Chart...